[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100493390":3},{"organization":4,"armGroups":7,"interventions":21,"overallOfficials":27,"centralContacts":31,"locations":39,"responsibleParty":89,"collaborators":91,"id":94,"slug":26,"hasResults":95,"nctId":96,"briefTitle":97,"officialTitle":98,"acronym":26,"eligibilityCriteria":99,"healthyVolunteers":95,"sex":100,"minAge":101,"maxAge":26,"enrollmentInfo":102,"targetDuration":26,"studyType":105,"phases":106,"briefSummary":108,"conditions":109,"keywords":26,"overallStatus":42,"whyStopped":26,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":120},{"fullName":5,"class":6},"Universitaire Ziekenhuizen KU Leuven","OTHER",[8,13,17],{"label":9,"type":6,"description":10,"interventionNames":11},"1. primary resection then follow-up","Scenario 1: primary resection then follow-up - Study-specific liquid biopsies will be collected in 98 patients, at the time of routine labs. Samples will be acquired before resection, at 6-8 weeks, 6 and 12 months after resection.",[12],"Other: Blood sample",{"label":14,"type":6,"description":15,"interventionNames":16},"2. chemoradiation followed by resection and follow-up","Scenario 2: chemoradiation followed by resection and follow-up - Study-specific liquid biopsies will be collected in 50 patients. Samples will be acquired before the start of chemoradiation, before surgery, 6-8 weeks, 6 and 12 months after surgery. A subgroup of patients will undertake adjuvant immunotherapy and will constitute Group 3. Timing of sampling will be adjusted accordingly as per study flowcharts.",[12],{"label":18,"type":6,"description":19,"interventionNames":20},"3. chemoradiation followed by resection followed by adjuvant immunotherapy","chemoradiation followed by resection followed by adjuvant immunotherapy - Study-specific liquid biopsies will be collected in 100 patients. Samples will be acquired before the start of chemoradiation, before surgery, 6-8 weeks after surgery and during adjuvant immunotherapy every 3 months including a sample at the end of treatment.",[12],[22],{"type":6,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"Blood sample","Retrospective collection of leftover tissue from standard of care biopsies or resection specimens and prospective collection of additional blood samples for study-specific analyses at specific timepoints, at the same time as routine labs are foreseen. No additional venipunctures are expected.",[9,14,18],null,[28],{"name":29,"affiliation":5,"role":30},"Jeroen Dekervel, MD","PRINCIPAL_INVESTIGATOR",[32,36],{"name":29,"role":33,"phone":34,"phoneExt":26,"email":35},"CONTACT","016344225","jeroen.dekervel@uzleuven.be",{"name":37,"role":33,"phone":34,"phoneExt":26,"email":38},"Filip Van Herpe, MD","filip.vanherpe@uzleuven.be",[40,54,65,76],{"facility":41,"status":42,"city":43,"state":26,"zip":26,"country":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"UZA","RECRUITING","Antwerp","Belgium",{"type":46,"coordinates":47},"Point",[48,49],4.40026,51.22047,{"lat":49,"lon":48},[52],{"name":53,"role":30,"phone":26,"phoneExt":26,"email":26},"Timon Vandamme, MD",{"facility":55,"status":42,"city":56,"state":26,"zip":26,"country":44,"cosmosGeoPoint":57,"geoPoint":61,"contacts":62},"UZ Gent","Ghent",{"type":46,"coordinates":58},[59,60],3.71667,51.05,{"lat":60,"lon":59},[63],{"name":64,"role":30,"phone":26,"phoneExt":26,"email":26},"Karen Geboes",{"facility":66,"status":42,"city":67,"state":26,"zip":26,"country":44,"cosmosGeoPoint":68,"geoPoint":72,"contacts":73},"UZLeuven","Leuven",{"type":46,"coordinates":69},[70,71],4.70093,50.87959,{"lat":71,"lon":70},[74,75],{"name":37,"role":33,"phone":26,"phoneExt":26,"email":26},{"name":29,"role":30,"phone":26,"phoneExt":26,"email":26},{"facility":77,"status":42,"city":78,"state":26,"zip":26,"country":44,"cosmosGeoPoint":79,"geoPoint":83,"contacts":84},"AZ Delta","Roeselare",{"type":46,"coordinates":80},[81,82],3.12269,50.94653,{"lat":82,"lon":81},[85,87],{"name":86,"role":33,"phone":26,"phoneExt":26,"email":26},"Katleen Kerstens",{"name":88,"role":30,"phone":26,"phoneExt":26,"email":26},"Jochen Decaestecker, MD",{"type":90,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR",[92],{"name":93,"class":6},"Kom Op Tegen Kanker","100493390",false,"NCT05704530","Liquid Biopsies in Esophageal Cancer","Personalized Multimodal Treatment for Resectable Esophageal Cancer by Detecting Minimal Residual Disease Using Circulating Tumor DNA: a Multicentric Prospective Study","Key inclusion criteria are:\n\n1. Male or female, age \\> 18 years\n2. New diagnosis of esophageal cancer, pathologically confirmed squamous cell carcinoma (ESCC) or adenocarcinoma (EAC)\n3. Clinically staged - cT1-4 N0-2 M0 (local or locally advanced, resectable)\n4. Eligible for multidisciplinary treatment as assessed by MDT\n5. Able to provide informed consent (ICF) according to Good Clinical Practice and national\u002FEuropean regulations\n\nKey exclusion criteria are:\n\n1. (Oligo)metastatic disease\n2. Histologically or cytologically confirmed diagnosis other than squamous cell carcinoma or adenocarcinoma (eg. neuroendocrine carcinoma, lymphoma…)\n3. Other active malignancies\n4. Previous exposure to chemoradiation (prior to MDT)\n5. Treatment plan after MDT: neoadjuvant chemotherapy with no radiation or chemoradiation with definitive intent (surgery is not planned)","ALL","18 Years",{"count":103,"type":104},248,"ESTIMATED","INTERVENTIONAL",[107],"NA","Purpose of this study is to determine the value of liquid biopsies, e.g. testing of minimal residual disease (MRD) by using liquid biopsies to measure circulating tumour DNA (ctDNA) at diagnosis and during the multimodal and multidisciplinary curative-intent treatment of resectable esophageal cancer.",[110],"Esophageal Cancer","2026-05-27",{"date":113,"type":114},"2026-06-01","ACTUAL",{"date":116,"type":114},"2023-03-29",{"date":118,"type":104},"2029-12-31",{"name":5,"class":6},4]